News - Myeloma Patients Europe

Latest News

Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”

March 27, 2024

Myeloma Patients Europe (MPE) will hold the webinar “AL amyloidosis treatment updates and patient experiences on new therapies” on Tuesday 16 April from 17:00 – 18:00 CEST. The webinar will be given by Dr. Moshe Gatt, Physician Researcher…

Snežana Doder, young myeloma patient: “When I talk about my journey, I compare it to a roller coaster. Everything happened very fast and unexpectedly”

March 25, 2024

My name is Snežana Doder and I´m from Serbia. When I talk about my journey, I compare it to a roller coaster. Everything happened very fast and unexpectedly. I had a very healthy lifestyle…

European Commission grants final approval for CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myeloma

March 21, 2024

The European Commission has granted the final approval for the extension of the marketing authorisation for idecabtagene vicleucel (ide-cel), a CAR-T treatment marketed by Bristol-Myers Squibb (BMS) as Abecma®. Ide-cel has previously been approved for…

Ana Rocha, young myeloma patient: “I didn’t let the diagnosis change me and I thought I should build something to help others newly diagnosed”

March 8, 2024

After the diagnosis, it took almost a month to start the treatments. The first one was on my birthday, and I felt that the universe was giving me a unique opportunity. I did six cycles…

EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

February 23, 2024

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA – the EU medicines regulator) has today given a positive recommendation for the extension of the marketing authorisation for the…

US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myeloma

February 22, 2024

The US Food and Drug Administration (FDA – the medicines regulator in the US) has granted approval to a “supplemental biologics license application” for teclistamab-cqvy (Tecvayli®). This means the existing FDA teclistamab license has been extended to…

AMEN provides medical information for Arabic speakers in Israel and beyond

February 13, 2024

The population of Israel today is 9.8 million people. Among them, 20% are Arabs (about 2 million people) whose first language is Arabic. Due to this, the Israel Multiple Myeloma Association, AMEN, decided to promote…

GSK announces results from interim analysis of the DREAMM-7 phase III trial

February 8, 2024

On 6 February 2024, GlaxoSmithKline (GSK) announced results from an interim analysis of the DREAMM-7 phase III trial presented at an American Society of Clinical Oncology (ASCO) online plenary session. The trial is evaluating belantamab…

December

January 2025

February

MO
TU
WE
TH
FR
SA
SU

30
31
1
2
3
4
5

6
7
8
9
10
11
12

13
14
15
16
17
18
19

20
21
22
23
24
25
26

27
28
29
30
31
1
2

Events for January

31st

No Events

Latest News

January 2025

Events for January

1st

Events for January

2nd

Events for January

3rd

Events for January

4th

Events for January

5th

Events for January

6th

Events for January

7th

Events for January

8th

Events for January

9th

Events for January

10th

Events for January

11th

Events for January

12th

Events for January

13th

Events for January

14th

Events for January

15th

Events for January

16th

Events for January

17th

Events for January

18th

Events for January

19th

Events for January

20th

Events for January

21st

Events for January

22nd

Events for January

23rd

Events for January

24th

Events for January

25th

Events for January

26th

Events for January

27th

Events for January

28th

Events for January

29th

Events for January

30th

Events for January

31st

Myeloma Patients Europe AISBL

PopUp